0000899243-17-024266.txt : 20171016 0000899243-17-024266.hdr.sgml : 20171016 20171016171606 ACCESSION NUMBER: 0000899243-17-024266 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20171013 FILED AS OF DATE: 20171016 DATE AS OF CHANGE: 20171016 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: SAXE JON S CENTRAL INDEX KEY: 0001114914 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-19825 FILM NUMBER: 171139373 MAIL ADDRESS: STREET 1: FIRST HORIZON PHARMACEUTICAL CORP STREET 2: 660 HEMBREE PKWY STE 106 CITY: ROSWELL STATE: GA ZIP: 30076 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: SCICLONE PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000880771 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 943116852 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 950 TOWER LANE STREET 2: SUITE 900 CITY: FOSTER CITY STATE: CA ZIP: 94404-2125 BUSINESS PHONE: 650-358-3456 MAIL ADDRESS: STREET 1: 950 TOWER LANE STREET 2: SUITE 900 CITY: FOSTER CITY STATE: CA ZIP: 94404-2125 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2017-10-13 1 0000880771 SCICLONE PHARMACEUTICALS INC SCLN 0001114914 SAXE JON S 950 TOWER LANE, SUITE 900 FOSTER CITY CA 94404 1 0 0 0 Common Stock 2017-10-13 4 D 0 135000 11.18 D 0 D Non-Qualified Stock Option (right to buy) 1.75 2017-10-13 4 D 0 30000 9.43 D 2018-06-10 Common Stock 30000 0 D Non-Qualified Stock Option (right to buy) 2.23 2017-10-13 4 D 0 30000 8.95 D 2019-06-09 Common Stock 30000 0 D Non-Qualified Stock Option (right to buy) 3.01 2017-10-13 4 D 0 30000 8.17 D 2020-06-10 Common Stock 30000 0 D Non-Qualified Stock Option (right to buy) 6.04 2017-10-13 4 D 0 30000 5.14 D 2021-06-30 Common Stock 30000 0 D Non-Qualified Stock Option (right to buy) 6.78 2017-10-13 4 D 0 30000 4.40 D 2022-06-07 Common Stock 30000 0 D Non-Qualified Stock Option (right to buy) 5.13 2017-10-13 4 D 0 30000 6.05 D 2023-06-27 Common Stock 30000 0 D Non-Qualified Stock Option (right to buy) 5.10 2017-10-13 4 D 0 30000 6.08 D 2024-06-12 Common Stock 30000 0 D Non-Qualified Stock Option (right to buy) 9.15 2017-10-13 4 D 0 30000 2.03 D 2025-06-11 Common Stock 30000 0 D Non-Qualified Stock Option (right to buy) 10.90 2017-10-13 4 D 0 30000 0.28 D 2027-06-08 Common Stock 30000 0 D Under its terms the option became exercisable in installments at the rate of one-twelfth of the shares subject to the option at the end of each one-month period from the date of grant (June 10, 2008), and became immediately exercisable and vested in full as of June 9, 2009. The option was canceled immediately prior to the merger of Issuer and Silver Delaware Investment Limited (the "Merger") in exchange for a cash payment per share from the Issuer in an amount equal to the excess of $11.18 per share over the exercise price. Under its terms the option became exercisable in installments at the rate of one-twelfth of the shares subject to the option at the end of each one-month period from the date of grant (June 9, 2009), and became immediately exercisable and vested in full as of June 9, 2010. Under its terms the option became exercisable in installments at the rate of one-twelfth of the shares subject to the option at the end of each one-month period from the date of grant (June 10, 2010), and became immediately exercisable and vested in full as of June 10, 2011. Under its terms the option became exercisable in installments at the rate of one-twelfth of the shares subject to the option at the end of each one-month period from the date of grant (June 30, 2011), and became immediately exercisable and vested in full as of June 30, 2012. Under its terms the option became exercisable in installments at the rate of one-twelfth of the shares subject to the option at the end of each one-month period from the date of grant (June 7, 2012), and became immediately exercisable and vested in full as of June 7, 2013. Under its terms the option became exercisable in installments at the rate of one-twelfth of the shares subject to the option at the end of each one-month period from the date of grant (June 27, 2013), and became immediately exercisable and vested in full as of June 27, 2014. Under its terms the option became exercisable in installments at the rate of one-twelfth of the shares subject to the option at the end of each one-month period from the date of grant (June 12, 2014), and became immediately exercisable and vested in full as of June 12, 2015. Under its terms the option became exercisable in installments at the rate of one-twelfth of the shares subject to the option at the end of each one-month period from the date of grant (June 11, 2015), and became immediately exercisable and vested in full as of June 11, 2016. Under its terms the option became exercisable in installments at the rate of one-twelfth of the shares subject to the option at the end of each one-month period from the date of grant (June 11, 2015), and became immediately exercisable and vested in full as of June 11, 2016. Under its terms the option became exercisable in installments at the rate of one-twelfth of the shares subject to the option at the end of each one-month period from the date of grant (June 8, 2017), and became immediately exercisable and vested in full as of the date ten (10) days prior to the Merger. /s/ Friedhelm Blobel, Attorney-in-Fact For: Jon S. Saxe 2017-10-16